Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm 
of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further 
development of Inovio's new commercial intradermal delivery device. DTRA's 
Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in 
developing a small, portable, battery-powered intradermal device branded as 
CELLECTRA(R) 3PSP to be used in the administration of Inovio's vaccines and 
therapies which include DTRA developed products. In addition to the development 
of CELLECTRA 3PSP, the new award will fund the investigation of DNA vaccines 
developed by the U.S. Army Medical Research Institute of Infectious Diseases 
(USAMRIID) using the new device.

Dr. Kate Broderick, Inovio's Senior Vice President of R&D and the Principal 
Investigator of the program, said, "We are honored that the U.S. Government 
considered highly of Inovio's track record of innovation and is providing this 
funding to support the further development of our commercial intradermal 
vaccine delivery device. Our CELLECTRA 3PSP is a small, portable user-friendly 
device which will allow broader access to Inovio's vaccines and 
immunotherapies, whether the vaccine is administered to our troops ready to be 
deployed around the world, at a local pharmacy or in challenging settings such 
as rural Africa." 

In recent Inovio sponsored clinical studies, intradermal delivery of Inovio's 
HIV, Ebola, and Zika vaccines resulted in consistently high and robust levels 
of immune responses. In an HIV vaccine study using intradermal delivery of 
PENNVAX(R) vaccine, Inovio demonstrated nearly 100% of participants displayed 
anti-HIV antibody and CD4+ T cell responses.

The project was sponsored by the U.S. Government through Other Transaction 
Agreement (OTA) number W15QKN-16-9-1002 between the Medical CBRN Defense 
Consortium (MCDC), and the Government.  The MCDC that is funding Inovio's 
device development, was formed in response to the U.S. government's interest in 
leveraging cutting edge R&D from commercial sources. This gives MCDC an agile 
and flexible way to develop medical countermeasures using new and innovative 
technology. Specifically, this program supports the U.S. Department of 
Defense's future medical pharmaceutical and diagnostic requirements as related 
to enhancing the mission effectiveness of military personnel.

About Inovio Pharmaceuticals, Inc.  

Inovio is an innovative biotechnology company focused on the discovery, 
development, and commercialization of its synthetic nucleic technology targeted 
against cancers and infectious diseases. Inovio's proprietary technology 
platform applies antigen sequencing and delivery to activate potent immune 
responses to targeted diseases. The technology functions exclusively in vivo, 
and has been demonstrated to consistently activate robust and fully functional 
T cell and antibody responses against targeted cancers and pathogens. Inovio's 
most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of 
HPV-related cervical pre-cancer. Also in development are Phase 2 
immuno-oncology programs targeting HPV-related cancers, bladder cancer, and 
glioblastoma, as well as platform development programs in hepatitis B, Zika, 
Ebola, MERS, and HIV. Partners and collaborators include AstraZeneca, 
Regeneron, Roche/Genentech, ApolloBio Corporation, GeneOne Life Science, The 
Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness 
Innovations, Defense Advanced Research Projects Agency, National Institutes of 
Health, National Institute of Allergy and Infectious Diseases, National Cancer 
Institute, HIV Vaccines Trial Network, Walter Reed Army Institute of Research, 
The Wistar Institute, and the University of Pennsylvania. For more information, 
visit www.inovio.com.

This press release contains certain forward-looking statements relating to our 
business, including our plans to develop DNA-based immunotherapies, our 
expectations regarding our research and development programs, including the 
planned initiation and conduct of clinical trials and the availability and 
timing of data from those trials. Actual events or results may differ from the 
expectations set forth herein as a result of a number of factors, including 
uncertainties inherent in pre-clinical studies, clinical trials and product 
development programs, the availability of funding to support continuing 
research and studies in an effort to prove safety and efficacy of 
electroporation technology as a delivery mechanism or develop viable DNA 
immunotherapies, our ability to support our pipeline of SynCon(R) active 
immunotherapy and vaccine products, the ability of our collaborators to attain 
development and commercial milestones for products we license and product sales 
that will enable us to receive future payments and royalties, the adequacy of 
our capital resources, the availability or potential availability of 
alternative therapies or treatments for the conditions targeted by us or our 
collaborators, including alternatives that may be more efficacious or cost 
effective than any therapy or treatment that we and our collaborators hope to 
develop, issues involving product liability, issues involving patents and 
whether they or licenses to them will provide us with meaningful protection 
from others using the covered technologies, whether such proprietary rights are 
enforceable or defensible or infringe or allegedly infringe on rights of others 
or can withstand claims of invalidity and whether we can finance or devote 
other significant resources that may be necessary to prosecute, protect or 
defend them, the level of corporate expenditures, assessments of our technology 
by potential corporate or other partners or collaborators, capital market 
conditions, the impact of government healthcare proposals and other factors set 
forth in our Annual Report on Form 10-K for the year ended December 31, 2018, 
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019  and 
other filings we make from time to time with the Securities and Exchange 
Commission. There can be no assurance that any product candidate in our 
pipeline will be successfully developed, manufactured or commercialized, that 
final results of clinical trials will be supportive of regulatory approvals 
required to market products, or that any of the forward-looking information 
provided herein will be proven accurate. Forward-looking statements speak only 
as of the date of this release, and we undertake no obligation to update or 
revise these statements, except as may be required by law.

CONTACTS:     
Investors:  Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com
Media:      Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com

SOURCE  Inovio Pharmaceuticals, Inc.